<DOC>
	<DOCNO>NCT02451137</DOCNO>
	<brief_summary>Primary Objective : Demonstrate clinical benefit Toujeo achieve individualized HEDIS HbA1c target ( &lt; 8 % age 65 year define comorbidities ( list Appendix G ) otherwise &lt; 7 % ) 6 month without document symptomatic ( BG 70mg/dl ) hypoglycemia time day baseline 6 month uncontrolled insulin naive patient type 2 diabetes initiate basal insulin therapy real world set . Secondary Objectives : Compare Toujeo commercially available basal insulins 6 12 month initiate insulin therapy real world set term : - Patient persistence assign basal insulin therapy - Risk hypoglycemia include incidence rate document symptomatic severe hypoglycemia - Changes HbA1c , fast plasma glucose , body weight - Differences patient- provider- report outcome ( include Diabetes Treatment Satisfaction Questionnaire Status Change Versions DTSQs DTSQc ) , Hypoglycemia Patient Questionnaire , patient provider report Global Effectiveness Scale ( GES ) - Healthcare resource utilization include hospitalization emergency department provider visit healthcare cost .</brief_summary>
	<brief_title>A `` Real World '' Trial Determine Efficacy Health Outcomes Toujeo ( ACHIEVE CONTROL REAL LIFE STUDY PROGRAM )</brief_title>
	<detailed_description>The total study duration per patient 53 week , consist 1-week screening period site , 26-week treatment period , 26-week extension period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Inclusion criterion : Patients T2DM , define American Diabetes Association/World Health Organization , diagnose least 1 year time screen visit , insufficiently control least 1 year treatment 2 following : oral agent ( metformin , sulfonylurea , thiazolidinediones , dipeptidyl peptidase4 [ DPP4 ] inhibitor , sodiumglucose cotransporter 2 [ SGLT2 ] inhibitor ) glucagonlike peptide1 ( GLP1 ) receptor agonist approve use insulin . Adult patient sign Informed Consent Form Health Insurance Portability Accountability Act ( HIPAA ) Authorization Form . Exclusion criterion : HbA1c &lt; 8.0 % &gt; 11.0 % . Males females &lt; 18 year age . Type 1 diabetes mellitus . Any clinically significant abnormality identify physical examination , laboratory test , vital sign time screen , major systemic disease result short life expectancy opinion Investigator would restrict limit patient 's successful participation duration study . Use product contain insulin ( Lantus , Levemir , Humulin , Novolin , Humalog , Novolog , Apidra , Afrezza ) since time diagnosis T2DM temporary use pregnancy hospitalization . Use product contain insulin ( Lantus , Levemir , Humulin , Novolin , Humalog , Novolog , Apidra , Afrezza ) occur within 3 month prior time screen . Use oral hypoglycemic agent note inclusion criterion , GLP1 receptor agonist approve use insulin , investigational agent ( drug , biologic , device ) within 3 month prior time screen . All contraindication commercially available insulin therapy warnings/precautions use display respective national product labeling product . Pregnancy lactation . Women childbearing potential effective contraceptive method . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>